title: [The use of genetic angiogenesis inductors in surgical treatment of chronic lower limb ischemia].
abstract: The efficacy and safety of gene-engineering recombinant constructions with endothelial growth factor gene and angiogenin for the treatment of the chronic lower limb ischemia were studied. 134 patients were included in prospective controlled study. The main group, who received both traditional treatment and genetic therapy, consisted of 74 patients. The rest 60 patients were included into the control group. Of 74 patients from the main group, genetic therapy was used together with conservative means in 39 patients and with reconstructive vascular operations in 35 patients. The gene-engineering angiogenesis stimulation therapy proved to be effective and safe. The combination of angiogenesis genetic stimulation with reconstructive vascular surgery demonstrated significantly better results, then monotherapy.
authors.forename: A V
authors.initials: AV
authors.lastname: Gavrilenko
authors.forename: D A
authors.initials: DA
authors.lastname: Voronov
authors.forename: N P
authors.initials: NP
authors.lastname: Bochkov
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007511:Ischemia / Q000628:therapy*; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D011446:Prospective Studies; D012259:Ribonuclease, Pancreatic / Q000627:therapeutic use*; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures
chemical_list: D043925:Angiogenesis Inducing Agents; C046366:angiogenin; D012259:Ribonuclease, Pancreatic